STOCK TITAN
  1. Home
  2. Sec-filings
  3. MIRM
  4. [Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity

Director at Mirum (MIRM) awarded deferred stock units and options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Mirum Pharmaceuticals director William Fairey reported new equity awards consisting of deferred stock units and stock options. He received 1,980 deferred stock units and options for 3,772 shares of common stock at an exercise price of $101.00 per share, all as compensation awards.

The options and deferred stock units vest on the first anniversary of the grant date, and in any case will be fully vested by the date of Mirum’s 2027 annual stockholder meeting. Each vested deferred stock unit will be settled in common stock upon a change in control of Mirum or within 60 days after his separation from service.

Positive

  • None.

Negative

  • None.
Insider Fairey William
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 3,772 $0.00 --
Grant/Award Deferred Stock Units 1,980 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 3,772 shares (Direct, null); Deferred Stock Units — 1,980 shares (Direct, null)
Footnotes (1)
  1. The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.
Deferred stock units granted 1,980 units Grant to director William Fairey on 2026-06-15
Stock options granted 3,772 options Grant to director William Fairey on 2026-06-15
Option exercise price $101.00 per share Stock Option (right to buy) underlying common stock
Option expiration 2036-06-14 Expiration date for stock options granted
Vesting schedule First anniversary of grant Awards fully vested by 2027 annual stockholder meeting
DSU payout triggers Change in control or separation Payout in stock upon earliest of these events
Deferred Stock Units financial
"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock"
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of 101.0000 per share"
change in control financial
"paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
annual stockholder meeting financial
"in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting"
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
separation from service financial
"within 60 days following separation from service with the Issuer"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fairey William
(Last)(First)(Middle)
C/O MIRUM PHARMACEUTICALS, INC.
989 E HILLSDALE BLVD., SUITE 300
(Street)
FOSTER CITY CALIFORNIA 94404
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$10106/15/2026A3,772 (1)06/14/2036Common Stock3,772$03,772D
Deferred Stock Units(2)06/15/2026A1,980 (2) (2)Common Stock1,980$01,980D
Explanation of Responses:
1. The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
2. Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.
/s/ Doug Sheehy, Attorney-in-Fact06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Mirum Pharmaceuticals (MIRM) report for William Fairey?

Mirum reported that director William Fairey received equity compensation awards, including 1,980 deferred stock units and stock options for 3,772 shares. These are grants, not open-market purchases or sales, and reflect standard non-cash board compensation at Mirum Pharmaceuticals.

How many deferred stock units did William Fairey receive from Mirum (MIRM)?

William Fairey received 1,980 deferred stock units from Mirum Pharmaceuticals. Each deferred stock unit represents a contingent right to receive one share of common stock once vesting and specified payment conditions, such as a change in control or separation from service, are met.

What stock options were granted to William Fairey by Mirum Pharmaceuticals (MIRM)?

Mirum granted William Fairey stock options covering 3,772 shares of common stock at an exercise price of $101.00 per share. These options vest on the first anniversary of the grant date and will be fully vested by the company’s 2027 annual stockholder meeting.

When do William Fairey’s Mirum (MIRM) deferred stock units and options vest?

Both the deferred stock units and stock options granted to William Fairey vest on the first anniversary of the grant date. The awards will in any case be fully vested on the date of Mirum Pharmaceuticals’ 2027 annual stockholder meeting, according to the filing.

Under what conditions are Mirum (MIRM) deferred stock units paid out to William Fairey?

Each vested deferred stock unit will be paid out in Mirum common stock upon the earliest of a change in control of the company or within 60 days following William Fairey’s separation from service, providing equity-based compensation aligned with his continued board service.

Are William Fairey’s Mirum (MIRM) equity awards open-market purchases or sales?

No, the reported transactions are compensation grants, not open-market trades. The Form 4 identifies them with code “A” as grant, award, or other acquisition, indicating board-related equity compensation rather than discretionary buying or selling of Mirum stock in the market.